CPX-351 vs 7+3: AML-MR Mutations Drive the Benefit of CPX-351 Over 7+3

With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating acute myeloid leukemia with mutations in measurable residual disease (AML-MR) by specifically targeting the genetic mutations driving the disease, leading to improved patient outcomes.

EP: 1.Overview of KOMET-007: Ziftomenib Use in NPM-1m or KMT2A-r AML

Now Viewing

EP: 2.CPX-351 vs 7+3: AML-MR Mutations Drive the Benefit of CPX-351 Over 7+3

EP: 3.Venetoclax Combination: IDH1 Inhibitor Plus 7+3 Leads to Higher Remission and MRD

Recent Videos